Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Parkinson's Disease With Cognitive Impairments Clear all
Completed Not applicable Interventional Results available

Cognitive Rehab for Parkinson's

NCT03836963
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
cognitive training, active control cognitive training, memory strategy training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

NCT00857532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2013 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Computer-based Cognitive Training for Individuals With Parkinson's Disease

NCT02225314
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
Brain Fitness, InSight, Active Control
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

NCT03713957
View directory record Official record
Conditions
Parkinson Disease
Interventions
GRF6021, Placebo
Drug · Other
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Englewood, Colorado • Doral, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Jul 24, 2026, 5:45 AM EDT
Completed No phase listed Observational

Cognitive Disparities in Parkinson's Disease

NCT07262658
View directory record Official record
Conditions
Parkinson Disease
Interventions
Will examine how Cardiovascular Disease risk, PD severity and social determinants impact neurocognitive impairment in Hispanics vs non-Hispanics Whites
Other
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
La Jolla, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jul 24, 2026, 5:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Moving Yourself in Space and Time: MYSTIC

NCT07697664
View directory record Official record
Conditions
Parkinson's Disease (PD), Alzheimer's Disease (AD) and Related Disorders, Older Adults (60 - 85 Years Old)
Interventions
Complex Rhythmic Movement Sequences (CRMS) Sessions
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 79 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Not applicable Interventional

A Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease

NCT01646333
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
Memory and Problem-Solving Intervention, Supportive Therapy
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

NCT04476017
View directory record Official record
Conditions
Parkinson Disease, Cognitive Dysfunction
Interventions
SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Long Beach, California • Port Charlotte, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 24, 2026, 5:45 AM EDT
Terminated Phase 1 Interventional

A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease

NCT01803945
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AVE8112, Placebo
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
35 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

NCT05318937
View directory record Official record
Conditions
Parkinson Disease, Cognitive Dysfunction
Interventions
SAGE-718-matching placebo, SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

NCT01211587
View directory record Official record
Conditions
Parkinson's Disease With Cognitive Impairments
Interventions
safinamide, placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
45 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
9
States / cities
Sunnyvale, California • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jul 24, 2026, 5:45 AM EDT
Terminated Not applicable Interventional

Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease

NCT02924194
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
stimulation ON, stimulation OFF
Device
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Treatment of Executive Dysfunction in Parkinson's Disease

NCT00286949
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Atomoxetine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

NCT00294554
View directory record Official record
Conditions
Parkinson's Disease, Cognitive Impairment, Dementia
Interventions
Memantine, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Jul 24, 2026, 5:45 AM EDT
Active, not recruiting Phase 2 Interventional

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

NCT04148391
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
Interventions
Placebo Oral Capsule, NYX-458
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
50 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Scottsdale, Arizona • Fresno, California • Simi Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Jul 24, 2026, 5:45 AM EDT
Recruiting Not applicable Interventional

High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease

NCT05268887
View directory record Official record
Conditions
Parkinson Disease
Interventions
GENUS device (Active Settings), GENUS device (Sham settings)
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
45 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 24, 2026, 5:45 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.

NCT07214974
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis, Alzheimer's Disease and Related Dementias, Parkinson's Disease, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Dementia (Diagnosis), Dementia MCI (Mild Cognitive Impairment)
Interventions
Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental, Control - Placebo Comparator
Behavioral · Device · Biological + 1 more
Lead sponsor
Noah Tech, Corp.
Industry
Eligibility
55 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palisades Park, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 24, 2026, 5:45 AM EDT
Terminated Not applicable Interventional

Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI

NCT01870518
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment, Dementia
Interventions
Bilateral GPi DBS, Bilateral STN DBS
Device
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Jul 24, 2026, 5:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

rTMS to Improve Cognition in Parkinson's

NCT03836950
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 24, 2026, 5:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effects of Multi-focal tDCS on Motor-cognitive Dysfunctions in Parkinson's Disease

NCT02656316
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Tel-Aviv Sourasky Medical Center
Government
Eligibility
25 Years to 90 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Phase 4 Interventional

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

NCT01497652
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline/Placebo, Rasagiline
Drug
Lead sponsor
Georgetown University
Other
Eligibility
40 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Jul 24, 2026, 5:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

NCT07154511
View directory record Official record
Conditions
Parkinson Disease, Parkinson Disease Dementia
Interventions
Tributyrin, Placebo
Drug
Lead sponsor
Prabesh Kanel
Other
Eligibility
45 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease

NCT03204526
View directory record Official record
Conditions
Parkinson Disease, Cognitive Impairment
Interventions
deep brain stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 24, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

NCT05104463
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia
Interventions
CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Drug
Lead sponsor
CuraSen Therapeutics, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • Lafayette, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 24, 2026, 5:45 AM EDT